Compare J B Hunt Transport Services Inc (JBHT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Tango Therapeutics Inc. — how do they compare? J B Hunt Transport Services Inc trades at $230.52 (market cap $21.52B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: J B Hunt Transport Services Inc is far larger — about 5.7× Tango Therapeutics Inc.'s market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and Tango Therapeutics Inc. for 0 Days on average.
| JBHT | TNGX | |
|---|---|---|
Market Cap | $21.52B | $3.75B |
Volume | 994,790 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $298.41 | $32.90 |
52-Week Low | $138.83 | $7.50 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $22.66B | $2.77B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $232.16, up 1.69% today, with a bearish technical signal but strong fundamental profitability. Recent earnings have consistently beaten expectations, with Q3 2026 results due October 15, 2026. The company maintains solid margins, with a net income margin of 5.31% and ROE of 18.45%, though revenue has declined from 2022 peaks. Cash flow from operations remains healthy at $1.68 billion for 2025.
Analyst consensus is bullish with a $287.93 price target, but near-term risks include rising costs pressuring Q3 earnings and multiple law firm investigations into potential securities claims. The stock offers upside if execution improves, but investors face headwinds from fuel expenses and legal overhangs.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
